Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

PAVmed Aktie 28040439 / US70387R1068

01.12.2025 04:29:45

Biotech Momentum Builds In After-Hours Trading As BioAtla, Entero, And Sonnet Climb

(RTTNews) - Several small-cap biotech and healthcare stocks posted notable gains in after-hours trading on Friday, November 28, 2025, despite limited fresh news flow. Below is a roundup of the key movers.

BioAtla Inc. (BCAB) shares surged in after-hours trading, climbing 13.94% to $1.03, after closing the regular session at $0.9040, up 6.27%. While there was no company-specific news on Friday, investors may still be reacting to BioAtla's November 21 announcement of financing agreements. The company entered into Pre-paid Advance Agreements with Yorkville Advisors Global and Anson Advisors Inc., securing a $7.5 million advance. Additionally, BioAtla signed a Standby Equity Purchase Agreement with Yorkville, granting the option to sell up to $15 million in common stock over three years at a 3% discount, subject to conditions.

Metagenomi Inc. (MGX) rose 5.71% in after-hours trading to $1.85, following a 3.55% gain during the regular session to $1.75. No new corporate updates were released on Friday, suggesting the move may be driven by investor sentiment or technical factors.

PAVmed Inc. (PAVM) advanced 5.72% after hours to $0.3900, reversing a slight decline earlier in the day when shares closed at $0.3650, down 0.44%. The company last reported earnings on November 13, posting a GAAP net loss of $6.3 million, or $(0.29) per share. Non-GAAP adjusted loss was $0.4 million, or $(0.02) per share, while revenue fell sharply to $5,000 from $996,000 in the prior year.

Precision BioSciences, Inc. (DTIL) gained 2.94% after hours to $5.60, building on a strong 6.46% rise during the regular session to $5.44. The company recently announced it will present Phase 1 data from its ELIMINATE-B trial of PBGENE-HBV at the Hep-DART 2025 meeting in Honolulu this December, which may be fueling investor optimism.

Reviva Pharmaceuticals Holdings, Inc. (RVPH) edged higher after hours, up 2.04% to $0.57, following a 7.66% gain during the regular session to $0.5625. The company last reported earnings on November 13, narrowing its quarterly net loss to $4.0 million, or $0.06 per share, compared to $8.4 million, or $0.25 per share, in the prior year period.

Sonnet BioTherapeutics Holdings, Inc. (SONN) rose 5.11% after hours to $3.91, recovering some ground after a steep 10.47% decline earlier in the day to $3.72. On November 18, the company announced it had adjourned its special meeting of stockholders to allow more time for voting on its proposed business combination with Hyperliquid Strategies Inc. and Rorschach I LLC. More than 95% of shares voted so far have supported the deal.

Entero Therapeutics, Inc. (ENTO) gained 3.68% after hours to $3.10, following a 5.28% rise during the regular session to $2.99. On Friday, the company announced it will rebrand as GridAI Technologies Corp. effective December 1, 2025, reflecting its acquisition of GRID AI Corp. The new ticker symbol "GRDX" will debut on the Nasdaq Capital Market alongside the name change.

Nachrichten zu Chanticleer Holdings Inc Registered Shs

  • Relevant
  • Alle
  • vom Unternehmen
  • ?
Keine Nachrichten verfügbar.

Analysen zu PAVmed Inc

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Krypto-Crash oder Einstiegs-Chance? – Bernhard Wenger von 21Shares zu Gast im BX Morningcall

Im BX Morningcall spricht Krypto-Experte Bernhard Wenger von @21shares über seinen Weg vom klassischen ETF-Geschäft in die Welt der Krypto-ETPs und erklärt, warum Bitcoin & Co. längst nicht ausgereizt sind. Er beleuchtet den Wandel von einem vorwiegend retailgetriebenen Markt hin zu immer mehr institutionellen Investoren, die über regulierte, physisch besicherte Produkte wie Bitcoin- und Krypto-ETPs investieren. Themen sind unter anderem Volatilität und „Krypto-Winter“, strenge Compliance- und Geldwäschereiregeln, Kostenstrukturen, Unterschiede im DACH-Raum sowie die Rolle des neuen US-Bitcoin-ETFs und des strategischen Investors FalconX für die nächste Wachstumsphase von 21Shares.

👉🏽 https://bxplus.ch/bx-musterportfolio/

Krypto-Crash oder Einstiegs-Chance? – Bernhard Wenger von 21Shares zu Gast im BX Morningcall

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
SMI-Kurs: 12’858.33 03.12.2025 17:30:48
Long 10’693.16 8.59 3SSMJU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com